Clin Infect Dis. 1997 Jan;24 Suppl 1:S151-3.

Antibiotic resistance: a view from the pharmaceutical industry.

Source

Department of Clinical Research and Development, SmithKline Beecham Pharmaceuticals, Harlow, Essex, England.

Abstract

The development of new antibiotics has been successful in significantly reducing morbidity and mortality. With increasing use there has occurred an increase in antibiotic resistance but not a parallel increase in new agents with significantly improved spectrum of activity. Without concerted action from the pharmaceutical industry, physicians, academia, health care providers, and governments, the prospects look gloomy.

PMID:: 8994797; [PubMed - indexed for MEDLINE]

Free full text

MeSH Terms, Substances

MeSH Terms

Substances

Anti-Bacterial Agents

LinkOut - more resources

Full Text Sources

Medical

Antibiotics - MedlinePlus Health Information

Supplemental Content

Related citations

The role of fundamental research and biotechnology in finding solutions to the global problem of antibiotic resistance. [Clin Infect Dis. 1997]
The role of fundamental research and biotechnology in finding solutions to the global problem of antibiotic resistance.
Hancock RE. Clin Infect Dis. 1997 Jan; 24 Suppl 1:S148-50.
Review Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry. [Infect Control Hosp Epidemiol. 2000]
Review Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry.
Lavin BS. Infect Control Hosp Epidemiol. 2000 Jan; 21(1 Suppl):S32-5.
Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005. [J Antimicrob Chemother. 2006]
Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.
Finch R, Hunter PA. J Antimicrob Chemother. 2006 Sep; 58 Suppl 1:i3-i22. Epub 2006 Sep 26.
Trends in antimicrobial drug development: implications for the future. [Clin Infect Dis. 2004]
Trends in antimicrobial drug development: implications for the future.
Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Clin Infect Dis. 2004 May 1; 38(9):1279-86. Epub 2004 Apr 14.
Review "Medicamentation" of society, non-diseases and non-medications: a point of view from social pharmacology. [Eur J Clin Pharmacol. 2005]
Review "Medicamentation" of society, non-diseases and non-medications: a point of view from social pharmacology.
Mbongue TB, Sommet A, Pathak A, Montastruc JL. Eur J Clin Pharmacol. 2005 Jun; 61(4):309-13. Epub 2005 May 14.

See reviews... See all...

Cited by 4 PubMed Central articles

Antimicrobial activity and mechanism of action of Nu-3, a protonated modified nucleotide. [Ann Clin Microbiol Antimicrob. 2011]
Antimicrobial activity and mechanism of action of Nu-3, a protonated modified nucleotide.
Cao S, Sun LQ, Wang M. Ann Clin Microbiol Antimicrob. 2011 Jan 14; 10:1. Epub 2011 Jan 14.
Development of Tyrocidine A analogues with improved antibacterial activity. [Bioorg Med Chem. 2007]
Development of Tyrocidine A analogues with improved antibacterial activity.
Marques MA, Citron DM, Wang CC. Bioorg Med Chem. 2007 Nov 1; 15(21):6667-77. Epub 2007 Aug 11.
Review Opinion: the clinical use of selective digestive decontamination. [Crit Care. 2000]
Review Opinion: the clinical use of selective digestive decontamination.
Kollef MH. Crit Care. 2000; 4(6):327-32. Epub 2000 Oct 2.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Antibiotic resistance: a view from the pharmaceutical industry.
Antibiotic resistance: a view from the pharmaceutical industry.
Clin Infect Dis. 1997 Jan ;24 Suppl 1:S151-3.

PubMed
LOC100038010 [Sus scrofa]
LOC100038010 [Sus scrofa]
Gene ID:100038010

Gene
RecName: Full=Envelope glycoprotein gp160; AltName: Full=Env polyprotein; Contai...
RecName: Full=Envelope glycoprotein gp160; AltName: Full=Env polyprotein; Contains: RecName: Full=Surface protein gp120; Short=SU; AltName: Full=Glycoprotein 120; Short=gp120; Contains: RecName: Full=Transmembrane protein gp41; Short=TM; AltName: Full=Glycoprotein 41; Short=gp41; Flags: Precursor
gi|119461|sp|P05883.1|ENV_HV2NZ

Protein
Professional topical fluoride applications--clinical efficacy and mechanism of a...
Professional topical fluoride applications--clinical efficacy and mechanism of action.
Adv Dent Res. 1994 Jul ;8(2):190-201.

PubMed
Changes in collagen cross-linking in degenerative disc disease and scoliosis.
Changes in collagen cross-linking in degenerative disc disease and scoliosis.
Spine (Phila Pa 1976). 1998 Dec 1 ;23(23):2545-51.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: